Scancell reports encouraging animal data using ImmunoBodies with Homspera
Scancell Holdings (LON:SCLP) , the cancer vaccine developer, announced that its collaboration with ImmuneRegen BioSciences (announced in June 2010) is already bearing some fruit. The companies have tested an ImmunoBody based DNA vaccine in combination with ImmuneRegen's Homspera vaccine adjuvant technology in an animal model. The results of this test indicate that Homspera increased the immune response over that of the DNA vaccine alone. Scancell's first ImmunoBody vaccine candidate, SCIB1 for melanoma, is currently in Phase I clinical trials in the UK. The Homspera compound was previously shown to increase the immune response of another potential melanoma (TRP-2 encoding) DNA vaccine. The ultimate aim of the collaboration between Scancell and ImmuneRegen is to develop a next generation melanoma vaccine therapy. The company also announced that it has appointed Matrix Corporate Capital LLP as joint broker along with Zeus Capital.
The SCLP share price has increased by 96% over the last year. Scancell Holdings Plc is currently graded c by LCF Research.
About the Author's Company
LCF Research is an independent, investor led investment research resource for private investors and fund managers. We do not seek to replicate the full coverage model of stockbrokers and independent research houses. Instead we aim to ask the key due diligence questions that should be posed prior to an investment… ...read more or visit website »
Disclaimer:
This note was prepared by LCF Research Limited using information provided by the subject company’s management or publically available news sources. No representations are made nor warranties given (express or implied) in relation to accuracy and completeness. This document is not an invitation to invest in the subject company and does not purport to contain all the necessary information that a prospective investor might require. LCF Research Limited recommends prospective investors to conduct their own thorough independent analysis of the subject company and the information contained in this note or referred to above.
Scancell Holdings PLC is a United Kingdom-based company. The Company’s principal activity of the consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. In April 2012, the Company completed recruitment to the Phase 1 clinical trial of SCIBI. In May 2012, the Company commenced recruitment and treatment of the first patient in the second part of it Phase 1/2 clinical trial of SCIBI. The Phase 2 part of the trial is conducted in five United Kingdom centers in Nottingham, Manchester, Newcastle, Leeds, and Southampton. On August 15, 2012, the Company announced the development of a platform technology, Moditope. more »
